Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

HIV virus, the immune system's fight against the infection, and the drugs administered to treat HIV. Painful HIV-DSP is characterized by significant pain in the feet and hands.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-DSP and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the successful completion of the C119 clinical trial with respect to NeurogesX' lead product candidate, NGX-4010, including the timing of announcement of results from such trial; filing for regulatory approval and the timing of such filings; the ability to obtain approval for and commercialize NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not lim
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Md. , June 3, 2015  GenVec, Inc. ... with Dr. David T. Curiel and his ... at St. Louis (WUSTL).  Dr. ... and the Cancer Biology Division within the Department of ... and the WUSTL team will create modified versions of ...
(Date:6/3/2015)... MENLO PARK, Calif. , June 3, 2015 ... novel small molecule drugs for cardiovascular diseases, today ... MPH, has been appointed Chief Executive Officer, effective ... of experience in global, high-growth enterprises, with a ... the improvement of human health. With expertise that ...
(Date:6/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/6xfc66/europe_ct_market ) ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... (CT) is an imaging process that customs special x-ray ... scans, of areas inside the body. It is also ... It is primarily used in the Cancer diagnosis process. ...
Breaking Medicine Technology:GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 2Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 3Armetheon Names Dr. Sanjay Kakkar as Chief Executive Officer 4Europe CT Market Report 2015-2019 - Growth, Trends And Forecasts 2
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will be honored ... Meeting. DIA’s Global Inspire Award program recognizes the organization’s ... commitment to service on a global scale. ... that recognizes the “Member of the Year” who consistently ... has contributed to the advancement of DIA’s mission. ...
(Date:6/3/2015)... 03, 2015 Researchers at the University ... mesothelioma and say the tried-and-true marker mesothelin is the ... article on the research. Click here to read ... Center for Asbestos Related Diseases say, even though a ... is still preferable to fibulin-3 for identifying mesothelioma. ...
(Date:6/3/2015)... June 03, 2015 Acne is the same ... be particularly stubborn to eliminate and hard to prevent. As ... in teens and young adults, in the years when the ... or oil,” says Jayme Bashian, director and lead medical aesthetician ... blackheads and cysts of acne are caused by oil and ...
(Date:6/3/2015)... First Choice Emergency Room , the ... United States, announced that it is opening its new ... , “I am pleased to announce that we are ... in the San Antonio area,” said Dr. James M. ... , First Choice Emergency Room is revolutionizing the ...
(Date:6/3/2015)... 03, 2015 Come on out in ... a 200-mile overnight relay beginning in Madison, Wisconsin on ... Saturday, June 13th. , For the 4th consecutive year, ... will run to raise money for the Brain Aneurysm ... members of the Neurosurgery staff from The University of ...
Breaking Medicine News(10 mins):Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:First Choice Emergency Room to Open New Facility in San Antonio, Texas 2Health News:4th Annual Ragnar Relay from Madison, WI to Chicago, IL Once Again Benefits Renowned Brain Aneurysm Foundation 2
... Protecting ... seeing up-close this summer simple and stylish , ... Miami, FL (PRWEB) June 2, 2010 -- VisAcuity.com today ... , , ,“We’ve invested nearly 12 months to gather this year’s exclusive collection of ...
... (May 29, 2010) -- Physician-scientists from NewYork-Presbyterian Hospital/Weill ... findings at the American Urological Association,s Annual Meeting ... Dr. Steven Kaplan, a urologist and ... Center, and Dr. Darracott Vaughan, senior author and ...
... A minimally invasive technique used to destroy kidney ... effectiveness as surgical removal of tumors in curbing cancer ... In an article available online in the journal ... and radiology at UT Southwestern Medical Center, reported the ...
... The National Institutes of Health (NIH) has awarded ... University a five-year, $3.9 million grant to study how ... Africa. The findings could alter public health approaches for ... "Most cases of XDR-TB are thought to arise when ...
... ... demanding enterprise customers with VMware and Microsoft Hyper-V environments. , ... (PRWEB) June 2, 2010 -- VKernel, the ... announced today the general availability of VKernel Optimization Pack 1.4. The latest version ...
... and perhaps more aggressive ones, found in heaviest men, study ... among prostate cancer patients appears to be linked to patient ... reveals. , The finding stems from work involving more ... 60 who underwent surgery between 2001 and 2007 to remove ...
Cached Medicine News:Health News:Sun Reading Glasses Collection Debuts 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 2Health News:NewYork-Presbyterian/Weill Cornell physician-scientists present at 2010 American Urological Meeting 3Health News:Ablation proved as effective as traditional surgery in treating kidney cancer 2Health News:Einstein awarded NIH grant to study drug-resistant TB 2Health News:Einstein awarded NIH grant to study drug-resistant TB 3Health News:VKernel Raises Scalability and Reporting Bar with Optimization Pack 1.4 2Health News:Size of Prostate Tumor Linked to Patients' Weight 2
The Urine Legionella Antigen ELISA kit detects the presence of Legionella pneumophila serogroup1 antigen in urine....
Measles IgG ELISA....
Toxoplasma IgM II ELISA....
Herpes Simplex Virus 2 IgG ELISA....
Medicine Products: